NO307048B1 - N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l - Google Patents

N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l

Info

Publication number
NO307048B1
NO307048B1 NO963526A NO963526A NO307048B1 NO 307048 B1 NO307048 B1 NO 307048B1 NO 963526 A NO963526 A NO 963526A NO 963526 A NO963526 A NO 963526A NO 307048 B1 NO307048 B1 NO 307048B1
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
drug
hydroxypyrrolidin
phenyl
ethyl
Prior art date
Application number
NO963526A
Other languages
English (en)
Norwegian (no)
Other versions
NO963526D0 (no
NO963526L (no
Inventor
Inge Stein
Holger Beeres
Klaus Beschmann
Steffen Neuenfeld
Andrew Barber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO963526D0 publication Critical patent/NO963526D0/no
Publication of NO963526L publication Critical patent/NO963526L/no
Publication of NO307048B1 publication Critical patent/NO307048B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO963526A 1995-08-26 1996-08-23 N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l NO307048B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19531464A DE19531464A1 (de) 1995-08-26 1995-08-26 N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid

Publications (3)

Publication Number Publication Date
NO963526D0 NO963526D0 (no) 1996-08-23
NO963526L NO963526L (no) 1997-02-27
NO307048B1 true NO307048B1 (no) 2000-01-31

Family

ID=7770485

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963526A NO307048B1 (no) 1995-08-26 1996-08-23 N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l

Country Status (25)

Country Link
US (1) US6060504A (pt)
EP (1) EP0761650B1 (pt)
JP (3) JP5023273B2 (pt)
KR (1) KR100436254B1 (pt)
CN (1) CN1081631C (pt)
AR (1) AR004679A1 (pt)
AT (1) ATE207895T1 (pt)
AU (1) AU716615B2 (pt)
BR (1) BR9603540A (pt)
CA (1) CA2184049C (pt)
CZ (1) CZ287783B6 (pt)
DE (2) DE19531464A1 (pt)
DK (1) DK0761650T3 (pt)
ES (1) ES2165948T3 (pt)
HU (1) HU226667B1 (pt)
MX (1) MX9603606A (pt)
NO (1) NO307048B1 (pt)
PL (1) PL187691B1 (pt)
PT (1) PT761650E (pt)
RU (1) RU2174976C2 (pt)
SI (1) SI0761650T1 (pt)
SK (1) SK282437B6 (pt)
TW (1) TW513407B (pt)
UA (1) UA41978C2 (pt)
ZA (1) ZA967200B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1828399A (en) * 1997-12-22 1999-07-12 Alza Corporation Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
KR101108014B1 (ko) * 2002-05-17 2012-01-25 티오가 파마슈티칼스, 인코포레이티드 선택성 아편제 수용체 조절인자로서 효과적인 화합물의 용도
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
AU2004288641B2 (en) * 2003-10-30 2010-08-12 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
EP2284987B1 (en) * 2009-08-12 2019-02-06 Braun GmbH Method and device for adjusting the frequency of a drive current of an electric motor
MX2012011604A (es) * 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CA3047325A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
MX9603606A (es) 1997-03-29
CZ243496A3 (en) 1997-03-12
EP0761650B1 (de) 2001-10-31
NO963526D0 (no) 1996-08-23
JPH09110830A (ja) 1997-04-28
TW513407B (en) 2002-12-11
AU716615B2 (en) 2000-03-02
DE19531464A1 (de) 1997-02-27
AR004679A1 (es) 1999-03-10
HUP9602346A3 (en) 1998-01-28
JP2009046501A (ja) 2009-03-05
SI0761650T1 (en) 2002-04-30
EP0761650A1 (de) 1997-03-12
JP5023273B2 (ja) 2012-09-12
NO963526L (no) 1997-02-27
PL315799A1 (en) 1997-03-03
KR970010744A (ko) 1997-03-27
ZA967200B (en) 1997-03-03
HUP9602346A2 (en) 1997-09-29
CN1151986A (zh) 1997-06-18
AU6214996A (en) 1997-03-06
SK282437B6 (sk) 2002-02-05
PL187691B1 (pl) 2004-09-30
JP2012246321A (ja) 2012-12-13
UA41978C2 (uk) 2001-10-15
ES2165948T3 (es) 2002-04-01
DE59608050D1 (de) 2001-12-06
CA2184049A1 (en) 1997-02-27
CN1081631C (zh) 2002-03-27
US6060504A (en) 2000-05-09
DK0761650T3 (da) 2002-02-18
RU2174976C2 (ru) 2001-10-20
PT761650E (pt) 2002-04-29
HU226667B1 (en) 2009-06-29
BR9603540A (pt) 1998-05-12
CA2184049C (en) 2007-10-02
ATE207895T1 (de) 2001-11-15
SK108996A3 (en) 1997-06-04
KR100436254B1 (ko) 2005-01-25
HU9602346D0 (en) 1996-10-28
CZ287783B6 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
EE9600118A (et) Uus peroraalne farmatseutiline annusvorm
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
NO20015816D0 (no) Indanylsubstituerte benzenkarbonamider, fremgangsmåter for fremstilling derav, anvendelse derav som medikament ogfarmasöytiske preparater inneholdende disse
FI973278A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
NO307048B1 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l
ZA200110217B (en) Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application.
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
HUP9901096A3 (en) Indole derivatives, preparation and use thereof, pharmaceutical composition containing these compounds
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
SI0752246T1 (en) Use of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl acetamide hydrochloride for the preparation of a medicament for the treatment of inflammatory diseases of the intestine
EE200100706A (et) A-grupi streptogramiinide derivaadid, nende valmistamismeetod ja farmatseutiline kompositsioon
DK0868911T3 (da) Rapamycinpræparater til oral indgivelse
EE9400296A (et) Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid
FR2733420B1 (fr) Preparations pectiques utilisables comme support de medicament
DZ2560A1 (fr) Préparations pharmaceutiques de cilansétrone stabilisées contre la racémisation.
DK0858459T3 (da) Nye sure pyrazolforbindelser, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler, deres nye anvendelse og farmaceutiske præparater med indhold deraf
EE04347B1 (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, neid sisaldav ravim ja farmatseutiline kompositsioon
NO305836B1 (no) Oksazolidin-2-on-forbindelser, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, samt anvendelse av forbindelsene til fremstilling av legemidler
AR019331A2 (es) Composicion farmaceutica que contiene un sensibilizador a insulina y un secretagogo de insulina.
HRP960076B1 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds, as well as medicaments containing them
PL345309A1 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
NO305834B1 (no) 4-merkaptobenzoylguanidiner, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, samt anvendelse av forbindelsene til fremstilling av legemidler
AU6308900A (en) Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees